| Basics |
Corvus Pharmaceuticals, Inc. Common Stock
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.
|
| IPO Date: |
March 21, 2016 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$310.77M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.19 | 3.70%
|
| Avg Daily Range (30 D): |
$0.11 | 2.96%
|
| Avg Daily Range (90 D): |
$0.13 | 3.32%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.52M |
| Avg Daily Volume (30 D): |
1.13M |
| Avg Daily Volume (90 D): |
.79M |
| Trade Size |
| Avg Trade Size (Sh.): |
215 |
| Avg Trade Size (Sh.) (30 D): |
146 |
| Avg Trade Size (Sh.) (90 D): |
127 |
| Institutional Trades |
| Total Inst.Trades: |
119 |
| Avg Inst. Trade: |
$1.42M |
| Avg Inst. Trade (30 D): |
$.66M |
| Avg Inst. Trade (90 D): |
$.6M |
| Avg Inst. Trade Volume: |
.23M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.71M |
| Avg Closing Trade (30 D): |
$.65M |
| Avg Closing Trade (90 D): |
$.65M |
| Avg Closing Volume: |
246.91K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.62
|
$.21
|
$-.16
|
|
Diluted EPS
|
$-.96
|
$-.13
|
$-.16
|
|
Revenue
|
$ M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -41.4M
|
$ 15.19M
|
$ -12.11M
|
|
Operating Income / Loss
|
$ -31.22M
|
$ -9.92M
|
$ -8.11M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -7.62M
|
$ -3.74M
|
$ 4.06M
|
|
PE Ratio
|
|
|
|
|
|
|
